Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4) have revolutionized the treatment of many malignancies, and have been of great interest in ACC. The gene discussed is PDCD1; the disease is adrenal cortex carcinoma.